Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00425
|
|||||
| Drug Name |
Cyclophosphamide
|
|||||
| Synonyms |
(+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide; ASTA; ASTA B518; Asta B 518; B 518; B-518; Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; C 0768; CB 4564; CB-4564; Ciclofosfamida; Ciclofosfamida [INN-Spanish]; Ciclophosphamide; Ciclophosphamide [INN]; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyclophosphamide, (+-)-Isomer; Cyclophosphamides; Cyclophosphamidum; Cyclophosphamidum [INN-Latin]; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cyklofosfamid [Czech]; Cytophosphan; Cytophosphane; Cytoxan; Cytoxan (TN); Cytoxan Lyoph; D,L-Cyclophosphamide; Endoxan; Endoxan (TN); Endoxan R; Endoxan-Asta; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Lyophilized Cytoxan; Mitoxan; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; Neosar; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox; Procytox (TN); Revimmune; Revimmune (TN); SK 20501; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Zyklophosphamid [German]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Lymphomas [ICD11:2B33.5] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C7H15Cl2N2O2P
|
|||||
| Canonical SMILES |
C1CNP(=O)(OC1)N(CCCl)CCCl
|
|||||
| InChI |
InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
|
|||||
| InChIKey |
CMSMOCZEIVJLDB-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 6055-19-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 261.079 | Topological Polar Surface Area | 41.6 | ||
| Heavy Atom Count | 14 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
0.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10090
,10524283
,11110909
,11335421
,11360660
,11363752
,11366314
,11368876
,11371419
,11374027
,11377038
,11406490
,11461632
,11484807
,11488962
,11490186
,11492119
,11494672
,11533313
,141705
,141706
,14848034
,17404801
,25765844
,29222060
,46505441
,47365072
,47440141
,47515205
,48334372
,48413505
,48415829
,48423195
,49855451
,50000789
,50105634
,50105635
,5080187
,51092052
,53777344
,53788477
,56310899
,56311422
,56313326
,56313987
,57288588
,598053
,7979009
,8151862
,87150
|
|||||
| ChEBI ID |
ChEBI:4027
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [2] | |
| References | ||||||
| 1 | Cyclophosphamide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.